R-CHOP vs. Pola-R-CHP: What's Different for DLBCL?

When starting treatment for Diffuse Large B-Cell Lymphoma (DLBCL) with curative intent, the core difference between standard R-CHOP and the newer Pola-R-CHP regimen is the swap of a single drug ^[1][2]. While both are multi-drug combinations, Pola-R-CHP replaces the traditional chemotherapy drug vincristine with polatuzumab vedotin, a newer targeted therapy ^[1]. Studies show that this swap can reduce the risk of the lymphoma returning for certain patients with higher-risk disease, but standard R-CHOP remains a highly effective and appropriate choice for many ^[3][4][2].

The Medicine Swap: Vincristine vs. Polatuzumab

R-CHOP has been the standard first-line regimen for DLBCL for decades. The acronym stands for a combination of five drugs: Rituximab, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone.

Pola-R-CHP uses four of those same medications, but it removes Oncovin (vincristine) and replaces it with polatuzumab vedotin ^[1][5]. Polatuzumab is an antibody-drug conjugate—a specialized medication designed to seek out the CD79b protein on the surface of B-cells (where DLBCL starts) and deliver chemotherapy directly into them ^[1]. However, “targeted” does not mean side-effect-free; because healthy B-cells also carry this protein, they are affected too, which contributes to the risk of side effects like low blood counts and infections ^[1][6].

What the POLARIX Trial Showed

The FDA (and other global regulators) approved Pola-R-CHP based on a large clinical study called the POLARIX trial. It is important to know that this trial specifically studied previously untreated adults with intermediate- or high-risk DLBCL ^[2]. The results do not automatically apply to all types of DLBCL (such as those with central nervous system involvement or transformed indolent lymphomas) or to patients with low-risk disease ^[2][7].

• Progression-Free Survival: The trial found that Pola-R-CHP improved progression-free survival (the time patients live without the disease growing, returning, or death from any cause). At a 5-year follow-up, about 64.9% of patients on Pola-R-CHP had not seen their disease progress, compared to 59.1% on R-CHOP ^[8].
• Overall Survival: Despite the roughly 6% absolute improvement in progression-free survival, the trial has not demonstrated a statistically significant difference in overall survival (how long patients live) between the two regimens ^[8][2].
• Side Effects and Safety: The overall rates of severe side effects were broadly comparable, but individual toxicities differed ^[2][8]. Both regimens carry serious shared risks, including doxorubicin-related cardiac toxicity, rituximab infusion reactions, hepatitis-B reactivation, and nerve damage (peripheral neuropathy) ^[9][10][6]. Notably, older patients receiving Pola-R-CHP had higher rates of febrile neutropenia (fever accompanied by a dangerously low white blood cell count) ^[6].
• Safety Reminder: Because of the risk of neutropenia, growth factor shots (G-CSF) are often used to reduce the risk of low white blood cells, but they do not prevent all infections ^[6]. Any fever during chemotherapy (often defined by centers as 100.4°F/38.0°C or higher) is a medical emergency requiring an urgent call to your oncology team.

How Your Doctor Decides

Your oncologist will look at your unique medical profile to recommend the best option. They generally weigh three main factors:

1. Your IPI Score (Risk Level): The International Prognostic Index (IPI) is a tool doctors use to estimate the risk of your lymphoma. It is calculated using five factors: your age, stage of disease, LDH blood level, performance status (how well you complete daily tasks), and the number of extranodal sites (cancer outside the lymph nodes) ^[7]. The strongest evidence for Pola-R-CHP is for patients with an IPI score of 2 to 5 ^[2]. For those with low-risk disease (an IPI score of 0 to 1), standard R-CHOP is highly effective and remains a strong standard of care ^[7].
2. Functional Status and Overall Health: Doctors look closely at your physical fitness, frailty, heart function, and other health conditions ^[11]. Older adults in the trial saw progression-free survival benefits from Pola-R-CHP, but these subgroup results are not guarantees for every individual ^[6]. Very frail patients, or those with significant other medical conditions or poor organ function, may need standard R-CHOP or an individualized, reduced-dose regimen like R-mini-CHOP to balance fighting the cancer with the body’s ability to safely tolerate treatment ^[12][6].
3. Logistics and Cost: Because polatuzumab is a newer targeted therapy, it is substantially more expensive than vincristine ^[13]. Your care team may need to consider insurance approvals, out-of-pocket costs, and available financial assistance programs when making a final plan.

The Treatment Schedule: Both treatments are given in 21-day cycles. In the POLARIX trial regimen, patients received 6 cycles of the Pola-R-CHP combination, followed by 2 additional cycles of just rituximab ^[2][1]. Steroids (prednisone) are taken orally for the first 5 days of each cycle ^[7][10]. Speak closely with your care team about the exact number of cycles, imaging tests, and schedules recommended for your unique situation.